Trial Profile
A Phase Ib Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors OSI Pharmaceuticals
- 12 Mar 2012 Actual patient number (19) and lead trial centre added as reported by ClinicalTrials.gov.
- 12 Mar 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
- 12 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.